These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 25399714)

  • 61. Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.
    Goetz MP; Sun JX; Suman VJ; Silva GO; Perou CM; Nakamura Y; Cox NJ; Stephens PJ; Miller VA; Ross JS; Chen D; Safgren SL; Kuffel MJ; Ames MM; Kalari KR; Gomez HL; Gonzalez-Angulo AM; Burgues O; Brauch HB; Ingle JN; Ratain MJ; Yelensky R
    J Natl Cancer Inst; 2014 Dec; 107(2):. PubMed ID: 25490892
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Race, common genetic variation, and therapeutic response disparities in heart failure.
    Taylor MR; Sun AY; Davis G; Fiuzat M; Liggett SB; Bristow MR
    JACC Heart Fail; 2014 Dec; 2(6):561-72. PubMed ID: 25443111
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Telomerase Gene (hTERT) and Survival: Results From Two Swedish Cohorts of Older Adults.
    Kalpouzos G; Rizzuto D; Keller L; Fastbom J; Santoni G; Angleman S; Graff C; Bäckman L; Fratiglioni L
    J Gerontol A Biol Sci Med Sci; 2016 Feb; 71(2):188-95. PubMed ID: 25452402
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Diagnosis and management of hereditary hemochromatosis.
    Salgia RJ; Brown K
    Clin Liver Dis; 2015 Feb; 19(1):187-98. PubMed ID: 25454304
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting.
    Kalman LV; Agúndez J; Appell ML; Black JL; Bell GC; Boukouvala S; Bruckner C; Bruford E; Caudle K; Coulthard SA; Daly AK; Del Tredici A; den Dunnen JT; Drozda K; Everts RE; Flockhart D; Freimuth RR; Gaedigk A; Hachad H; Hartshorne T; Ingelman-Sundberg M; Klein TE; Lauschke VM; Maglott DR; McLeod HL; McMillin GA; Meyer UA; Müller DJ; Nickerson DA; Oetting WS; Pacanowski M; Pratt VM; Relling MV; Roberts A; Rubinstein WS; Sangkuhl K; Schwab M; Scott SA; Sim SC; Thirumaran RK; Toji LH; Tyndale RF; van Schaik R; Whirl-Carrillo M; Yeo K; Zanger UM
    Clin Pharmacol Ther; 2016 Feb; 99(2):172-85. PubMed ID: 26479518
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The role of drug transporters in the kidney: lessons from tenofovir.
    Moss DM; Neary M; Owen A
    Front Pharmacol; 2014; 5():248. PubMed ID: 25426075
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Developing patient-friendly genetic and genomic test reports: formats to promote patient engagement and understanding.
    Haga SB; Mills R; Pollak KI; Rehder C; Buchanan AH; Lipkus IM; Crow JH; Datto M
    Genome Med; 2014; 6(7):58. PubMed ID: 25473429
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A proposed clinical decision support architecture capable of supporting whole genome sequence information.
    Welch BM; Loya SR; Eilbeck K; Kawamoto K
    J Pers Med; 2014 Apr; 4(2):176-99. PubMed ID: 25411644
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Smokers' beliefs about the tobacco control potential of "a gene for smoking": a focus group study.
    Waters EA; Ball L; Carter K; Gehlert S
    BMC Public Health; 2014 Nov; 14():1218. PubMed ID: 25424390
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The IPD and IMGT/HLA database: allele variant databases.
    Robinson J; Halliwell JA; Hayhurst JD; Flicek P; Parham P; Marsh SG
    Nucleic Acids Res; 2015 Jan; 43(Database issue):D423-31. PubMed ID: 25414341
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cyclosporine and methotrexate-related pharmacogenomic predictors of acute graft-versus-host disease.
    Laverdière I; Guillemette C; Tamouza R; Loiseau P; Peffault de Latour R; Robin M; Couture F; Filion A; Lalancette M; Tourancheau A; Charron D; Socié G; Lévesque É
    Haematologica; 2015 Feb; 100(2):275-83. PubMed ID: 25425682
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations.
    González-Galarza FF; Takeshita LY; Santos EJ; Kempson F; Maia MH; da Silva AL; Teles e Silva AL; Ghattaoraya GS; Alfirevic A; Jones AR; Middleton D
    Nucleic Acids Res; 2015 Jan; 43(Database issue):D784-8. PubMed ID: 25414323
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Telomere length and the clinical phenotype of frailty in older adults undergoing cardiac surgery.
    Brault ME; Ohayon SM; Kwan R; Bergman H; Eisenberg MJ; Boivin JF; Morin JF; Langlois Y; Autexier C; Afilalo J
    J Am Geriatr Soc; 2014 Nov; 62(11):2205-7. PubMed ID: 25413191
    [No Abstract]   [Full Text] [Related]  

  • 74. Pharmacogenetic prediction of individual variability in drug response based on CYP2D6, CYP2C9 and CYP2C19 genetic polymorphisms.
    Chaudhry SR; Muhammad S; Eidens M; Klemm M; Khan D; Efferth T; Weisshaar MP
    Curr Drug Metab; 2014; 15(7):711-8. PubMed ID: 25429673
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Impact of common ABCB1 polymorphism on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites.
    Karaźniewicz-Łada M; Danielak D; Rubiś B; Burchardt P; Komosa A; Lesiak M; Główka F
    J Clin Pharm Ther; 2015 Apr; 40(2):226-31. PubMed ID: 25430046
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pharmacogenetics of osteoporosis.
    Marini F; Brandi ML
    Best Pract Res Clin Endocrinol Metab; 2014 Dec; 28(6):783-93. PubMed ID: 25432352
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The quality of hereditary haemochromatosis guidelines: a comparative analysis.
    Vanclooster A; Cassiman D; Van Steenbergen W; Swinkels DW; Janssen MC; Drenth JP; Aertgeerts B; Wollersheim H
    Clin Res Hepatol Gastroenterol; 2015 Apr; 39(2):205-14. PubMed ID: 25441394
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pharmacogenomics and the resulting impact on psoriasis therapies.
    Foulkes AC; Warren RB
    Dermatol Clin; 2015 Jan; 33(1):149-60. PubMed ID: 25412789
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prostate cancer risk prediction based on complete prostate cancer family history.
    Albright F; Stephenson RA; Agarwal N; Teerlink CC; Lowrance WT; Farnham JM; Albright LA
    Prostate; 2015 Mar; 75(4):390-8. PubMed ID: 25408531
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Recommendations for the management of patients with familial hypercholesterolemia.
    Feldman DI; Blaha MJ; Santos RD; Jones SR; Blumenthal RS; Toth PP; Sperling LS; Martin SS
    Curr Atheroscler Rep; 2015 Jan; 17(1):473. PubMed ID: 25404096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.